Northern Trust Corp boosted its position in shares of Blueprint Medicines Corp (NASDAQ:BPMC) by 0.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 497,135 shares of the biotechnology company’s stock after acquiring an additional 726 shares during the period. Northern Trust Corp owned 1.13% of Blueprint Medicines worth $45,588,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in BPMC. Bank of Montreal Can lifted its position in Blueprint Medicines by 2,719.3% during the 4th quarter. Bank of Montreal Can now owns 6,428 shares of the biotechnology company’s stock worth $484,000 after acquiring an additional 6,200 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in Blueprint Medicines by 11.5% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 188,320 shares of the biotechnology company’s stock worth $14,202,000 after acquiring an additional 19,485 shares during the last quarter. Strs Ohio lifted its position in Blueprint Medicines by 69.6% during the 4th quarter. Strs Ohio now owns 3,900 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 1,600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Blueprint Medicines by 57.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 680 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new position in Blueprint Medicines during the 4th quarter worth $227,000. 97.64% of the stock is owned by hedge funds and other institutional investors.
Top 10 Biotech Stocks To Watch For 2019: Alnylam Pharmaceuticals Inc.(ALNY)
Advisors' Opinion:- [By Brian Orelli]
Earlier this week, Dicerna released promising interim phase I data for its lead drug, DCR-PHXC, in patients with primary hyperoxaluria type 1 and type 2. The company plans to start a trial to be used to support an FDA approval in the first quarter of 2019, but that'll put it behind Alnylam Pharmaceuticals (NASDAQ:ALNY), which is about to start a phase 3 study testing its drug, lumasiran, in patients with primary hyperoxaluria type 1. Hopefully, Dicerna can use some of its new capital to help accelerate enrollment in its trial to try to catch up to Alnylam.
- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.
- [By Jim Crumly]
Commercial success for Tegsedi is not a done deal even if it's approved worldwide; Alnylam Pharmaceuticals' (NASDAQ:ALNY) competing drug patisiran was approved by the FDA on Aug. 10. Alnylam's clinical testing showed cardiac benefits for patients whose cardiovascular systems have been affected by the disease, and Alnylam believes that will give patisiran an advantage over Tegsedi. But in the conference call, Akcea executives brushed off that concern and pointed to the advantage Tegsedi has in being an injection that can be delivered at home, versus patisiran, which is administered intravenously in a clinic. We shall see.
- [By Keith Speights]
It's not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum's market cap is less than $350 million while Alnylam's market cap is close to $10 billion.
Top 10 Biotech Stocks To Watch For 2019: Biogen Idec Inc(BIIB)
Advisors' Opinion:- [By Chris Lange]
The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Biogen Inc. (NASDAQ: BIIB) which traded down nearly 4% at $329.58. The stock's 52-week range is $244.28 to $348.84. Volume was 1.2 million matching the daily average of 1.2 million shares.
- [By Chris Lange]
Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 3.45 million shares from the previous 3.50 million. The stock recently traded at $274.50, within a 52-week range of $244.28 to $370.57.
- [By Keith Speights]
Shares of Biogen Inc. (NASDAQ:BIIB) were up 15.2% as of 11:35 a.m. EDT on Friday after the biotech, along with partner Eisai, reported encouraging results from a phase 2 clinical study of BAN2401 in treating Alzheimer's disease. Patients taking BAN2401 achieved statistically significant improvement compared to patients on placebo after 18 months in slowing progression of Alzheimer's disease and in the reduction of amyloid accumulations in the brain.
Top 10 Biotech Stocks To Watch For 2019: Amgen Inc.(AMGN)
Advisors' Opinion:- [By Keith Speights]
Amgen Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE) actually have quite a bit in common. They co-market one of the world's best-selling drugs, Enbrel. They both face some headwinds with declining sales of older drugs. Each company has promising new drugs. And both stocks are up by nearly the same percentage over the last 12 months.
- [By Logan Wallace]
Philadelphia Trust Co. decreased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 8.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 74,676 shares of the medical research company’s stock after selling 6,501 shares during the quarter. Amgen makes up 1.2% of Philadelphia Trust Co.’s portfolio, making the stock its 22nd biggest position. Philadelphia Trust Co.’s holdings in Amgen were worth $13,784,000 as of its most recent SEC filing.
- [By Lee Jackson]
This biotech giant remains a top stock for investors to buy and a safe way to play the massive potential growth in biosimilars. Amgen Inc. (NASDAQ: AMGN) has been a biotechnology pioneer since 1980 and has grown to be one of the world’s leading independent biotech companies. It has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
- [By Ethan Ryder]
Wayne Hummer Investments L.L.C. trimmed its position in shares of Amgen (NASDAQ:AMGN) by 11.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,311 shares of the medical research company’s stock after selling 303 shares during the period. Wayne Hummer Investments L.L.C.’s holdings in Amgen were worth $394,000 at the end of the most recent quarter.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.46 million shares from the previous level of 9.49 million. Shares were last seen at $171.94, in a 52-week trading range of $152.16 to $201.23.
- [By Todd Campbell]
One of these two drugs is Amgen's (NASDAQ:AMGN) Repatha, and the other is Praluent, which was co-developed by Sanofi SA (NYSE:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN). Both drugs launched to billion-dollar blockbuster expectations, but because they're complex biologics that are expensive to make, they cost about $14,000 per year. Their high cost, plus the fact that they're injected rather than taken orally, may make them best suited for patients with stubbornly high cholesterol who are at the greatest risk of heart disease.
Top 10 Biotech Stocks To Watch For 2019: ArQule Inc.(ARQL)
Advisors' Opinion:- [By Joseph Griffin]
ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Lisa Levin] Gainers Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter. Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants. Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday. SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday. Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results. Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter. Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday. Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday. ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday. Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday. Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Logan Wallace]
ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.
Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.
- [By Logan Wallace]
BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.
A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.
No comments:
Post a Comment